Syncom Formulations (India) Ltd
NSE:SYNCOMF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Water Ways Technologies Inc
XTSX:WWT
|
CA |
|
F
|
Fobi AI Inc
XBER:WMV
|
CA |
|
A
|
Axis Bank Ltd
BSE:532215
|
IN |
|
Eris Lifesciences Ltd
NSE:ERIS
|
IN |
|
Auplata Mining Group SA
PAR:ALAMG
|
GF |
|
H
|
Hong Kong Johnson Holdings Co Ltd
HKEX:1955
|
HK |
|
B
|
Bell-Park Co Ltd
TSE:9441
|
JP |
|
Q
|
Qeeka Home (Cayman) Inc
HKEX:1739
|
CN |
Syncom Formulations (India) Ltd
EPS (Diluted)
Syncom Formulations (India) Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Syncom Formulations (India) Ltd
NSE:SYNCOMF
|
EPS (Diluted)
₹0
|
CAGR 3-Years
32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
EPS (Diluted)
₹66
|
CAGR 3-Years
-33%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-5%
|
|
|
Cipla Ltd
NSE:CIPLA
|
EPS (Diluted)
₹56
|
CAGR 3-Years
20%
|
CAGR 5-Years
15%
|
CAGR 10-Years
10%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
EPS (Diluted)
₹45
|
CAGR 3-Years
37%
|
CAGR 5-Years
35%
|
CAGR 10-Years
11%
|
|
|
Lupin Ltd
NSE:LUPIN
|
EPS (Diluted)
₹129
|
CAGR 3-Years
N/A
|
CAGR 5-Years
39%
|
CAGR 10-Years
11%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
EPS (Diluted)
₹67
|
CAGR 3-Years
40%
|
CAGR 5-Years
13%
|
CAGR 10-Years
4%
|
|
Syncom Formulations (India) Ltd
Glance View
Syncom Formulation India Ltd. is a pharmaceutical company, which engages in the development, manufacture, and marketing of healthcare products. The company is headquartered in Indore, Madhya Pradesh. The firm manufactures and markets more than 300 pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquid orals, liquid vials and ampoule injections and dry vial injections, dry syrups, ointments and inhalers. Its segments include Pharmaceuticals Drugs & Formulations, Trading of Commodities and Renting of property. Its product categories include tablets, capsules, ointments, injections, liquid-oral and packaging variants. The company offers various products, including generics, alpha adrenoceptor agonist, analgesic, antipyretic, anti-inflammatory, anti-ulcer agents, antibiotic, antidepressant, antiviral, cephelo sporins, cortico steroid, estrogen, cough suppressant and sedative anticonvulsant, among others. The firm operates in more than 15 countries across the world.
See Also
What is Syncom Formulations (India) Ltd's EPS (Diluted)?
EPS (Diluted)
0.5
INR
Based on the financial report for Mar 31, 2025, Syncom Formulations (India) Ltd's EPS (Diluted) amounts to 0.5 INR.
What is Syncom Formulations (India) Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
32%
Over the last year, the EPS (Diluted) growth was 96%. The average annual EPS (Diluted) growth rates for Syncom Formulations (India) Ltd have been 32% over the past three years .
